Skip to main content

Table 2 Treatment patterns among Medicare-eligible Stage IV ER + breast cancer patients who did not receive HER2 targeted agents

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Characteristic

Study cohort

With > 2 months of follow-up to allow for treatment

 

  N

285

  %

87.7%

  Receiving surgery within 4 months of diagnosis

 

   N

110

   %

38.60%

  Receiving radiation within 4 months of diagnosis

 

   N

91

   %

31.93%

  Receiving any medication

 

   N

212

   %

74.4%

   Type of treatment received (at any time post-index)

 

    Chemotherapy alone

15.1%

    Aromatase Inhibitors (AI) therapy

 

     Anastrazole monotherapy

11.8%

     Letrozole monotherapy

9.4%

     Exmenestane monotherapy

1.4%

     Multiple AI therapies

2.4%

    Non-AI therapy

 

     Fulvestrant monotherapy

4.2%

     Tamoxifen monotherapy

1.9%

     Toremifene monotherapy

0.0%

     Megestrol monotherapy

0.9%

     Multiple non-AI therapies

0.5%

    Chemotherapy combined with AI therapy

11.8%

    Chemotherapy combined with non-AI therapy

15.1%

    AI therapy combined with non-AI therapy

10.4%

    Chemotherapy combined with AI and non-AI therapy

15.1%

   Duration of any treatment (months)

 

    Mean ± SD

12.9 ± 9.1

    Median

11.0

   Duration of AI treatment (months), among those with any AI use

 

    Mean ± SD

11.0 ± 8.1

    Median

9.5

   Duration of non-AI treatment (months), among those with any non-AI use

    Mean ± SD

5.6 ± 5.4

    Median

4.0

   Duration of chemo treatment (months), among those with any chemo use

    Mean ± SD

8.5 ± 7.2

    Median

6.0